Noha M. Badawi

Brain-targeted intranasal aripiprazole via modified chitosan nanoparticles: controlled release, pharmacokinetics, and pharmacodynamics.

Schizophrenia remains one of the most disabling mental disorders, and effective therapy is still limited by the difficulty of delivering drugs across the blood-brain barrier. Aripiprazole (Ari), a first-line atypical antipsychotic, exhibits restricted clinical performance due to poor solubility, extensive hepatic metab...